OneMedNet (NASDAQ:ONMD) (NASDAQ:ONMD) is a leading provider of cloud-based eClinical solutions designed to streamline and enhance the management of clinical trials. Since its founding in 2004, the company has focused on delivering integrated software tools that cover every stage of study execution, from protocol design to patient close‐out. OneMedNet’s platform combines electronic data capture (EDC), randomization and trial supply management (RTSM), and clinical trial management system (CTMS) capabilities in a single, scalable environment tailored for biopharmaceutical sponsors, contract research organizations (CROs) and academic research institutions.
The company’s flagship offering includes a flexible EDC module that supports customizable case report forms, real‐time data validation and audit trails to ensure regulatory compliance. Its RTSM functionality automates patient randomization and investigational product distribution, while the CTMS component provides study oversight through milestone tracking, site payments and resource planning. In addition to these core modules, OneMedNet offers eConsent solutions, electronic patient‐reported outcomes (ePRO) tools and a range of analytics and reporting features that enable sponsors to make data‐driven decisions and accelerate time to market.
OneMedNet serves a diverse client base across North America, Europe and Asia-Pacific, with a particular focus on oncology, rare disease and central nervous system studies. The platform is designed to support Phase I through IV trials across multiple therapeutic areas, accommodating both large global programs and smaller investigator‐initiated studies. By leveraging a hosted, software‐as‐a‐service model, the company offers rapid study setup, low upfront costs and continuous product enhancements delivered via quarterly releases.
The company’s executive team is led by CEO David J. Marshall, a veteran of the life sciences technology sector, and CFO Maria L. Rodriguez, who brings more than a decade of experience in healthcare finance. Under their leadership, OneMedNet has invested heavily in research and development to incorporate advances in artificial intelligence, risk‐based monitoring and decentralized trial functionality. The organization maintains strategic partnerships with leading research centers and industry consortia, further solidifying its reputation as an innovative collaborator in the clinical research ecosystem.
